Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’

Core Insights - Intellia Therapeutics, Inc. (NASDAQ:NTLA) experienced significant stock performance, reaching an all-time high of $26.46 before closing at $24.47, reflecting a 19.72% increase in one day due to "buy" recommendations from two investment firms [1][2] Group 1: Stock Performance - Intellia's stock surged to an all-time high of $26.46 during trading, closing at $24.47, marking a daily increase of 19.72% [1] - Zacks Research upgraded Intellia's stock to a "buy" recommendation, indicating an upward trend in earnings estimates from Wall Street analysts [2] Group 2: Analyst Ratings and Market Potential - JMP Securities assigned an "outperform" rating to Intellia with a price target of $33, driven by a positive outlook for its hereditary angioedema (HAE) program [3] - The drug candidate Ionvo-Z is projected to capture a 19% market share, translating to a potential market opportunity of $2.8 billion [3]